The PSU study involved 95 volunteers who had already had two shots of Sinovac vaccine.
The volunteers were divided into two groups, with the first group given the mini-booster and the second group given a full shot of AstraZeneca.
After they were given the mini-booster, volunteers’ immunity – measured by BAU/mL or binding antibody units per millilitre – soared from an average 128.7 to 1,300.
Meanwhile, the full AstraZeneca dose generated immunity of 1,600 BAU/mL.
Some volunteers had their Sinovac jabs 4-8 weeks apart and others 8-12 weeks apart, but there was no significant difference in the mini-booster’s effect on either group, said researchers. Both groups saw their antibodies and T-cells surge to high levels after receiving one-fifth of an AstraZeneca dose, they added.
Researchers also reported no serious side effects among the 95 volunteers.
The mini-booster jabs were administered subcutaneously (under the skin) while the full dose was injected into the muscle. No serious side effects were reported by volunteers in either group. The mini-booster generated fewer physical side effects such as fever, chills, and aches, but more swelling, redness, heat and itching at the injection site.
Published : September 14, 2021